Date of Award


Document Type

Dissertation - Pacific Access Restricted

Degree Name

Doctor of Philosophy (Ph.D.)


Pharmaceutical and Chemical Sciences

First Advisor

Mamoun M. Alhamadsheh, Ph.D.

First Committee Member

Miki S. Park, Ph.D.

Second Committee Member

Melanie Felmlee, Ph.D.

Third Committee Member

Roshanak Rahimian, Pharm.D., Ph.D.

Fourth Committee Member

Qinliang Zhao, Ph.D.


Ligand-targeted therapeutics are a rapidly growing class of anticancer agents. This class of therapeutics is typically bifunctional molecules that use a targeting moiety to selectively deliver potent, typically nonspecific, cytotoxic agents to cancer cells while sparing normal cells. The low-molecular-weight of ligant-targeted therapeutics allows for better tumor penetration, especially in the case of solid tumors where the size of antibodies is a limiting factor for effective treatment. Unfortunately, the poor pharmacokinetic profiles of many of these conjugates present a challenge, which limits their tremendous therapeutic potential. Dose-limiting toxicity is also observed due to the need for high doses and frequent administration. This dissertation describes our work to develop a fundamentally new approach for targeting cancer. Our approach could potentially reduce the toxicity and enhance the pharmacokinetic properties of targeted anticancer agents, which would decrease dosing frequency and improve the lives of cancer patients.



To access this thesis/dissertation you must have a valid email address and log-in to Scholarly Commons.



Rights Statement

Rights Statement

In Copyright. URI:
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).